Juret P, Tanguy A, Girard A, Le Talaer J Y, Abbatucci J S, Le Pecq J B, Paoletti C
Nouv Presse Med. 1979 Apr 21;8(18):1495-8.
A new derivative of ellipticine, hydroxy-9-methyl-2-ellipticinium acetate, was found to be a useful anti-tumor drug in advanced cancers which could not be treated any longer successfully by any other procedure. In our series of 100 patients, the best results were obtained with bone metastases from breast carcinomas and with anaplastic thyroid carcinomas. Most patients usually received a weekly perfusion of 80 mg/m2. The main characteristic of this drug is its lack of hematologic, and hepatic toxicity. No renal trouble was observed during the first year, but 2 deaths from renal insufficiency occured during the 18th and 15th month of treatment. The most frequent side effect consists of digestive troubles (nausea, vomiting) which rarely compelled to stop the treatment (4 times in 100 patients).
椭圆玫瑰树碱的一种新衍生物，即羟基 - 9 - 甲基 - 2 - 醋酸椭圆玫瑰树碱，被发现是一种对晚期癌症有用的抗肿瘤药物，这些晚期癌症已无法通过任何其他方法成功治疗。在我们的100例患者系列中，乳腺癌骨转移和间变性甲状腺癌取得了最佳效果。大多数患者通常每周接受80mg/m²的灌注。这种药物的主要特点是缺乏血液学和肝毒性。治疗的第一年未观察到肾脏问题，但在治疗的第18个月和第15个月分别有2例死于肾功能不全。最常见的副作用是消化系统问题（恶心、呕吐），很少迫使患者停止治疗（100例患者中有4次）。
